The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SMMT | -13.84% | +459.38% | +41.05% | +77% |
| S&P | +12.65% | +91.73% | +13.89% | +225% |
Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Menlo Park, CA.
Learn about some of the leading cancer stocks in the U.S. stock market this year.
The company's prospects improve with every clinical win.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.04M | -110.0% |
| Market Cap | $15.34B | -3.3% |
| Market Cap / Employee | $96.50M | 0.0% |
| Employees | 159 | 51.4% |
| Net Income | -$231.79M | -312.0% |
| EBITDA | -$234.17M | -303.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $238.88M | 153.9% |
| Accounts Receivable | $0.00M | 0.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.71M | -35.6% |
| Short Term Debt | $2.72M | -90.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -241.08% | -186.5% |
| Return On Invested Capital | -115.87% | -3.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$95.09M | -194.4% |
| Operating Free Cash Flow | -$95.02M | -194.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 30.04 | 36.60 | 45.83 | 59.15 | 60.47% |
| Price to Tangible Book Value | 30.17 | 36.78 | 46.09 | 59.62 | 61.01% |
| Enterprise Value to EBITDA | -193.91 | -207.74 | -27.29 | -64.59 | -75.73% |
| Return on Equity | -94.9% | -123.9% | -328.3% | -292.5% | 299.45% |
| Total Debt | $7.22M | $6.45M | $5.55M | $5.43M | -83.30% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
